You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

460 Results
Regimen
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
  • megestrol - oral tablets
Oct 2017
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Sep 2025
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Aug 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Sep 2017
Regimen
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Jun 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to specific criteria.
Jun 2025

Pages